US 12,239,699 B2
Immunogen for broad-spectrum influenza vaccine and application thereof
Jianqing Xu, Shanghai (CN); Xiaoyan Zhang, Shanghai (CN); and Xinci Xie, Shanghai (CN)
Assigned to Shanghai Public Health Clinical Center, Shanghai (CN)
Appl. No. 17/275,253
Filed by Shanghai Public Health Clinical Center, Shanghai (CN)
PCT Filed Sep. 11, 2018, PCT No. PCT/CN2018/105020
§ 371(c)(1), (2) Date May 7, 2021,
PCT Pub. No. WO2020/051766, PCT Pub. Date Mar. 19, 2020.
Prior Publication US 2022/0118077 A1, Apr. 21, 2022
Int. Cl. A61K 39/145 (2006.01); A61K 39/275 (2006.01); A61P 31/16 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/145 (2013.01) [A61K 39/275 (2013.01); A61P 31/16 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10343 (2013.01); C12N 2710/24134 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12N 2800/00 (2013.01)] 4 Claims
 
1. An anti-influenza vaccine immunogen, wherein the immunogen comprises the sequences shown in SEQ ID No: 1 or SEQ ID No: 2, or a combination thereof.